(Reuters) – The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc’s anti-inflammation drug Dupixent to treat eczema in young children, the two companies said on Tuesday.
(Reporting by Bhanvi Satija and Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)
